RSLV-132: Phase I started

Resolve began a dose-escalation Phase I trial to evaluate 0.3-10 mg/kg RSLV-132 in 32 healthy volunteers. Next quarter, Resolve plans to start a Phase IIa trial in SLE patients. In February 2013, Reso...